HEPAGENE THERAPEUTICS INC

Overview

About

HEPAGENE THERAPEUTICS INC has a total of 26 patent applications. It increased the IP activity by 40.0%. Its first patent ever was published in 2016. It filed its patents most often in China, WIPO (World Intellectual Property Organization) and EPO (European Patent Office). Its main competitors in its focus markets pharmaceuticals, organic fine chemistry and biotechnology are NAEJA PHARMACEUTICAL INC, BRISTOL MYERS SQUIBB PHARMA COMPANY and NEUROCRINE BIOSCIENCES INC.

Patent filings in countries

#	Country	Total Patents
#1	China	8
#2	WIPO (World Intellectual Property Organization)	6
#3	EPO (European Patent Office)	5
#4	Republic of Korea	3
#5	Canada	2
#6	United States	2

#	Technology
#1	Therapeutic chemical compounds
#2	Medical preparations
#3	Heterocyclic compounds
#4	Sugars
#5	Peptides
#6	Special acyclic compounds
#7	Climate change mitigation in goods production
#8	Steroids

#	Name	Total Patents
#1	Xu Xiaodong	26

Publication	Filing date	Title
WO2019099307A1	2018-11-09	Urea derivatives as inhibitors of ask1
WO2019099203A1	2018-10-31	Oxazole and thiazole derivatives as inhibitors of ask1
KR20200031127A	2018-07-24	Apoptosis protein dimer peptide inhibitor
CN109963849A	2017-10-27	Nitrogen-containing heterocycle compound as FXR regulator
CN108707173A	2017-04-06	Avermectin derivatives as FXR conditioning agents
CN107973790A	2016-10-22	Heterocyclic FXR conditioning agent
CN107973834A	2016-10-22	Chlolic acid derivatives as FXR/TGR5 conditioning agents